Rankings / Sleep & Recovery

Suzetrigine (Journavx / VX-548)

Sleep & Recovery · Selective Nav1.8 sodium channel inhibitor

Tier A+

Reviewed by Read Off Label · Last reviewed · How we grade

opioidprescription
8.2 / 10
Tier A+
Ev 8 Bn 6.5 Sf 9

Bottom line

Read Off Label grades Suzetrigine (Journavx / VX-548) as A+ (8.2/10) based on strong evidence, moderate-high for acute pain benefit magnitude, and a low-risk safety profile.

Vertex Pharmaceuticals.

Studied, labeled, or reported-use context: 100 mg PO loading dose then 50 mg PO every 12 hours — Rx; not individualized guidance.

What the evidence says

Vertex Pharmaceuticals. First new acute pain mechanism in decades. Major clinical relevance because it offers non-opioid acute pain relief — directly addressing the opioid crisis. Vertex pricing ~$15-20/dose vs ~$1 for generic opioids is the practical adoption challenge. Currently studied in chronic pain (DPN, lumbosacral radiculopathy) but Phase 2 chronic results were less impressive — efficacy may be acute-pain-specific.

Mechanism

Selective inhibitor of voltage-gated sodium channel Nav1.8 expressed almost exclusively on peripheral pain-sensing neurons; blocks pain signal transmission peripherally without CNS effects — no opioid receptor activity, no abuse potential, no sedation; first-in-class non-opioid acute pain mechanism

Studied, labeled, or reported dose & route

100 mg PO loading dose then 50 mg PO every 12 hours

This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.

Citations

A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.

Common questions

What does the evidence show about Suzetrigine (Journavx / VX-548)'s effects?
Read Off Label rates the evidence for Suzetrigine (Journavx / VX-548) as Strong and the benefit magnitude as moderate-high for acute pain, producing an overall grade of A+ (8.2/10). Vertex Pharmaceuticals.
What safety findings are reported for Suzetrigine (Journavx / VX-548)?
Suzetrigine (Journavx / VX-548) has a low risk profile in the database. Low (mild constipation, headache, nausea; no respiratory depression; no abuse potential — not scheduled) Legal status: Rx (FDA-approved Jan 2025 for moderate-to-severe acute pain).
What doses or routes are reported for Suzetrigine (Journavx / VX-548)?
100 mg PO loading dose then 50 mg PO every 12 hours This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
How does Suzetrigine (Journavx / VX-548) work?
Selective inhibitor of voltage-gated sodium channel Nav1.8 expressed almost exclusively on peripheral pain-sensing neurons; blocks pain signal transmission peripherally without CNS effects — no opioid receptor activity, no abuse potential, no sedation; first-in-class non-opioid acute pain mechanism

This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.